Developer docs
API playgroundTry for free, no card

Search company profiles

Jain Foundation

Full company profile

uuid000a728

Namestring
Jain Foundation
Legal namestring
Jain Foundation Inc.
Company typeenum
Private
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, muscular dystrophy research, patient registry services, biomedical research grants, animal model distribution
Industry4 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
NAICS code4 codes
  • Voluntary Health Organizations813212
  • Grantmaking Foundations813211
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Services-Misc Health & Allied Services, Nec8090
Product category
Muscular Dystrophy Research
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Endowment and Family Funding
TypeData Monetisation
Description

The Jain Foundation is a non-profit organization funded primarily through the Jain family's endowment. The foundation does not generate commercial revenue but distributes funds through research grants to advance its mission of finding cures for dysferlinopathy and CNNM2-associated diseases.

jain-foundation.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Project CNNM2
Description

A separate team formed in September 2025 investigating diseases related to mutations in the CNNM2 gene, which regulates magnesium handling, with present-from-birth symptoms in the kidney and sometimes the brain.

jain-foundation.org
Core offering1 text field

The Jain Foundation is a non-profit research foundation that funds, coordinates, and conducts research to find cures for dysferlinopathy (LGMD2B/LGMDR2/Miyoshi Myopathy 1) and CNNM2-associated diseases. It provides free research tools (animal models, cell lines, antibodies, DNA constructs), human biospecimens, natural history clinical data, preclinical MRI platform services, and a patient registry to support basic, translational, and clinical research globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83% retention rate achieved in COS clinical study vs. 70% industry average
+3 more records
Product overview1 text field

The Jain Foundation is a non-profit research foundation founded in 2005 that operates two distinct research programs: the Dysferlinopathy Program (for dysferlinopathy/LGMD2B) and Project CNNM2 (launched September 2025 for CNNM2-related diseases). The foundation provides a comprehensive research ecosystem including the Dysferlin Registry patient database, Clinical Outcome Studies (COS and COS2), Data Resources with natural history and omics datasets, Human Biospecimens, Animal Models including multiple mouse strains and zebrafish, a Preclinical MRI Platform, the Automated LGMD Diagnostic Assistant (ALDA), and the Dysferlin Research Blog for knowledge dissemination. These products and services are designed to support basic, translational, and clinical research toward developing treatments for dysferlinopathy.

Product and service10 records
1Dysferlin Registry
CategoryPatient Registry
Description

A patient registry for individuals with dysferlinopathy (LGMD2B, LGMDR2, Miyoshi Myopathy 1) that supports patient registration, inquiry, and recruitment for clinical studies and trials. The registry is the foundation's primary tool for patient engagement and clinical trial readiness.

2Project CNNM2
CategoryResearch Program
Description

A research program launched in September 2025 focused on finding cures for diseases associated with mutations in the CNNM2 gene, which regulates magnesium handling, with present-from-birth symptoms in the kidney and sometimes the brain. The program provides research funding, registry support, and is developing dedicated research tools.

3Clinical Outcome Study (COS)
CategoryClinical Research Program
Description

International multicenter clinical study for dysferlinopathy that evaluated over 200 genetically confirmed patients with medical, physiotherapy, MRI, and questionnaire assessments over 2-10 years. Conducted at 16 sites in 9 countries, providing comprehensive natural history data.

4Data Resources
CategoryData Service
Description

Access to natural history clinical data sets, miRNA, RNA, protein, and cytokine data sets, and mouse proteomic and lipidomic data sets for dysferlin research. Provided free of charge to researchers.

5Human Biospecimens
CategoryResearch Resource
Description

Plasma, serum, DNA, RNA, fibroblasts, cell lines, and biopsy material from genetically confirmed dysferlinopathy patients, including samples from the Clinical Outcome Study. Provided to researchers upon request.

6Animal Models
CategoryResearch Tool
Description

Dysferlin-deficient mouse lines including Bla/J, A/J, SJL/J, Dysf-/-, KI32, and R1925X strains, plus zebrafish models, available for research worldwide through Jackson Laboratory with foundation approval.

7Preclinical MRI Platform
CategoryResearch Platform
Description

MRI platform developed specifically for evaluation of potential therapeutic interventions in mouse models of dysferlinopathy, supporting preclinical drug development.

8Automated LGMD Diagnostic Assistant (ALDA)
CategoryDiagnostic Tool
Description

An automated diagnostic assistant tool for healthcare professionals to aid in diagnosing limb-girdle muscular dystrophy, including dysferlinopathy and related LGMD subtypes.

9Research Grants Program
CategoryResearch Funding
Description

Grant-based funding for basic, translational, and clinical research to academic and industry researchers studying dysferlinopathy and CNNM2-associated diseases. The foundation solicits proposals and monitors funded project progress.

10Study Recruitment Service
CategoryResearch Service
Description

Support for recruiting dysferlinopathy patients from the Dysferlin Registry for surveys, studies, and clinical trials, enabling researchers to access a trial-ready patient cohort.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for biomarker discovery and validation in dysferlinopathy. PROOF Centre (Centre of Excellence for the Prevention of Organ Failure) provided expertise in computation, 'omic' science, and biomarker workflow. Project resulted in identification of blood-based biomarkers associated with differences in muscle function.

2Wellstone Muscular Dystrophy Specialized Research Center (University of Iowa)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wellstone Center maintains a repository of broad spectrum of skeletal muscle biopsies from neuromuscular disease patients including dysferlinopathy. Provides biopsy samples to researchers upon request.

jain-foundation.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

JAX serves as the repository for multiple dysferlin-deficient mouse models (Bla/J cryopreserved stock, A/J, SJL/J, Dysf-/- lines, and others). The foundation maintains private live colonies that are distributed through JAX upon foundation approval. Also hosts the KI32 private colony.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

WiCell provides iPS cell lines from dysferlinopathy patients, including JFNY iPS line from a patient heterozygous for the c.5713C>T mutation. Part of the dysferlin-deficient collection.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Isabelle Richard at Genethon developed the Bla/J mouse strain by crossing the A/J dysferlin mutation onto C57BL/6 background. Strain was donated to Jackson Laboratory in collaboration with Jain Foundation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on macrophage-mediated mechanisms in dysferlinopathy pathogenesis. Dr. Vicki R Kelley leads studies on M1-like vs M2-like macrophage phenotypes and their role in non-resolving muscle inflammation.

7Dr. Frances Lemckert (Children's Hospital at Westmead & Children's Medical Research Institute)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on proteomics and lipidomics analysis of dysferlin-deficient muscle, including studies on exon 40a knockout mice. Generated comprehensive datasets from 18-week old mice quadricep muscles.

jain-foundation.org
8Dr. Bradley S. Launikonis (University of Queensland)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research on calcium handling and ryanodine receptor (RyR1) in dysferlinopathy. Study published in Nature Communications (2025) showing how dysferlin deficiency impacts calcium leak through RyR1 and how this relates to muscle-specific pathology.

jain-foundation.org
9Dr. Pascal Bernatchez (University of British Columbia)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research on the link between dysferlin and cholesterol metabolism. Studies show ApoE knockout mice crossed with dysferlin-deficient mice develop worse muscle phenotype, indicating cholesterol may play a role in muscular dystrophy.

jain-foundation.org
10Dr. Christoph Handschin (University of Basel)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research on metabolic dysregulation in dysferlinopathy. Study published in Life Sci Alliance (2025) revealing unexpected role for dysferlin in muscle cell energy metabolism and showing PGC-1alpha overexpression accelerates disease.

jain-foundation.org
11Dr. Doug Anderson (University of Rochester)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Development of StitchR technology for full-length dysferlin protein expression using dual AAV vector approach. Technology 'stitches' together two RNA fragments to create full-length transcripts for large gene delivery.

jain-foundation.org
12Dr. Volker Straub (John Walton Muscular Dystrophy Research Center, Newcastle University)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leadership of International Clinical Outcome Study (COS) for Dysferlinopathy. Team provided patient data for studies on respiratory impairment prediction using upper limb assessments.

jain-foundation.org
13Dr. Miranda Grounds (University of Western Australia)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research on mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy. Study investigates why daily glucocorticoid administration causes accelerated muscle strength loss in dysferlinopathy patients.

jain-foundation.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

International conference partnership for neuromuscular disease research. Foundation provides travel grants for researchers presenting dysferlin-related work at TREAT-NMD conferences.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Annual conference partnership. Foundation staff attend MDA Clinical & Scientific Conference to engage with the muscular dystrophy research community and share dysferlin-specific research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site for gene therapy trial in dysferlinopathy using AAVrh74 vector. Trial focuses on non-ambulant patients age 18+ with established DYSF mutations on both alleles.

17CNNM2 Patients and Researchers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

New program (September 2025) investigating diseases related to CNNM2 gene mutations affecting magnesium handling. Foundation provides dedicated emails (CNNM2ResearchFunding@jain-foundation.org, CNNM2Patients@jain-foundation.org) and is developing research tools including CNNM2 mouse models and cell lines.

jain-foundation.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Coalition to Cure Calpain 3 (C3)
TypeDirect peer
Description

Patient-founded nonprofit focused on finding treatments for LGMD2A/R1 (calpain 3 deficiency). Operates an almost identical playbook to Jain: maintains a patient registry, funds academic research, and provides free research tools to the field. The most direct structural analog to the Jain Foundation within the LGMD nonprofit ecosystem.

TypeDirect peer
Description

Disease-specific nonprofit dedicated to Duchenne muscular dystrophy. Operates a patient registry, funds research, develops standards of care, and partners with industry on clinical trials. Same patient-founded, vertically integrated rare-disease foundation model that Jain has applied to dysferlinopathy.

TypeDirect peer
Description

Dysferlinopathy-focused patient foundation providing support, education, and advocacy for individuals with LGMD2B/R2 and Miyoshi Myopathy. Directly overlaps with Jain's patient community and serves as a complementary peer in the same disease space.

TypeDirect peer
Description

Patient-driven nonprofit focused on facioscapulohumeral muscular dystrophy. Operates a patient registry, funds research, and convenes the field through scientific meetings — the same integrated model Jain uses for dysferlinopathy. Comparable rare-disease foundation structure.

TypeDirect peer
Description

Spinal muscular atrophy nonprofit that has driven one of the most successful translational models in rare disease, including standards of care, patient registries, and partnered clinical trials. Functions as a benchmark for what a well-run disease-specific rare disease research foundation can achieve.

6Myotonic Dystrophy Foundation (MDF)
TypeDirect peer
Description

Patient-founded nonprofit focused on myotonic dystrophy (DM1/DM2). Maintains a patient registry, funds research grants, and convenes an annual scientific meeting. Comparable to Jain in scope, scale, and operating model within the muscular dystrophy nonprofit ecosystem.

TypeBroad incumbent
Description

Large, established muscular dystrophy nonprofit supporting research and care across all MD subtypes including dysferlinopathy. Operates MDA Care Centers, a broad research grant program, and an annual Clinical & Scientific Conference. Broader and more diversified than Jain, but overlaps significantly on patient support and research funding.

TypeBroad incumbent
Description

International network for neuromuscular disease research and clinical trial infrastructure, including patient registries and care standards. Partners with Jain on conference grants and convening; relevant as a cross-disease infrastructure peer rather than a direct fundraiser.

TypeDirect peer
Description

French neuromuscular disease nonprofit and parent of Généthon, which developed the Bla/J dysferlin mouse strain now maintained by Jain. The closest European analog to a vertically integrated rare-disease research foundation, combining fundraising, gene therapy development, and clinical infrastructure.

TypeOthers
Description

Umbrella advocacy organization for the rare-disease community in the US, providing policy advocacy, patient assistance programs, and convening for disease-specific organizations like Jain. Adjacent rather than competitive, but a key peer in the rare-disease ecosystem in which Jain operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jain Foundation

Muscular Dystrophy Researchjain-foundation.org

Jain Foundation firmographics

Firmographics
Name
Jain Foundation
Legal name
Jain Foundation Inc.
Website
https://jain-foundation.org
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Jain Foundation industry classification

Industry
Product category
Muscular Dystrophy Research
NAICS
Voluntary Health Organizations (813212), Grantmaking Foundations (813211), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases

Keywords

  • Rare disease research
  • Muscular dystrophy research
  • Patient registry services
  • Biomedical research grants
  • Animal model distribution

Where Jain Foundation is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Jain Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Endowment and Family Funding: The Jain Foundation is a non-profit organization funded primarily through the Jain family's endowment. The foundation does not generate commercial revenue but distributes funds through research grants to advance its mission of finding cures for dysferlinopathy and CNNM2-associated diseases.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Jain Foundation product offering

Product offering

Core offering

The Jain Foundation is a non-profit research foundation that funds, coordinates, and conducts research to find cures for dysferlinopathy (LGMD2B/LGMDR2/Miyoshi Myopathy 1) and CNNM2-associated diseases. It provides free research tools (animal models, cell lines, antibodies, DNA constructs), human biospecimens, natural history clinical data, preclinical MRI platform services, and a patient registry to support basic, translational, and clinical research globally.

Product overview

The Jain Foundation is a non-profit research foundation founded in 2005 that operates two distinct research programs: the Dysferlinopathy Program (for dysferlinopathy/LGMD2B) and Project CNNM2 (launched September 2025 for CNNM2-related diseases). The foundation provides a comprehensive research ecosystem including the Dysferlin Registry patient database, Clinical Outcome Studies (COS and COS2), Data Resources with natural history and omics datasets, Human Biospecimens, Animal Models including multiple mouse strains and zebrafish, a Preclinical MRI Platform, the Automated LGMD Diagnostic Assistant (ALDA), and the Dysferlin Research Blog for knowledge dissemination. These products and services are designed to support basic, translational, and clinical research toward developing treatments for dysferlinopathy.

Differentiator

Problem solved

Functional benefit

Brands

  • Project CNNM2: A separate team formed in September 2025 investigating diseases related to mutations in the CNNM2 gene, which regulates magnesium handling, with present-from-birth symptoms in the kidney and sometimes the brain.

Products and services

  • Dysferlin Registry A patient registry for individuals with dysferlinopathy (LGMD2B, LGMDR2, Miyoshi Myopathy 1) that supports patient registration, inquiry, and recruitment for clinical studies and trials. The registry is the foundation's primary tool for patient engagement and clinical trial readiness.
  • Project CNNM2 A research program launched in September 2025 focused on finding cures for diseases associated with mutations in the CNNM2 gene, which regulates magnesium handling, with present-from-birth symptoms in the kidney and sometimes the brain. The program provides research funding, registry support, and is developing dedicated research tools.
  • Clinical Outcome Study (COS) International multicenter clinical study for dysferlinopathy that evaluated over 200 genetically confirmed patients with medical, physiotherapy, MRI, and questionnaire assessments over 2-10 years. Conducted at 16 sites in 9 countries, providing comprehensive natural history data.
  • Data Resources Access to natural history clinical data sets, miRNA, RNA, protein, and cytokine data sets, and mouse proteomic and lipidomic data sets for dysferlin research. Provided free of charge to researchers.
  • Human Biospecimens Plasma, serum, DNA, RNA, fibroblasts, cell lines, and biopsy material from genetically confirmed dysferlinopathy patients, including samples from the Clinical Outcome Study. Provided to researchers upon request.
  • Animal Models Dysferlin-deficient mouse lines including Bla/J, A/J, SJL/J, Dysf-/-, KI32, and R1925X strains, plus zebrafish models, available for research worldwide through Jackson Laboratory with foundation approval.
  • Preclinical MRI Platform MRI platform developed specifically for evaluation of potential therapeutic interventions in mouse models of dysferlinopathy, supporting preclinical drug development.
  • Automated LGMD Diagnostic Assistant (ALDA) An automated diagnostic assistant tool for healthcare professionals to aid in diagnosing limb-girdle muscular dystrophy, including dysferlinopathy and related LGMD subtypes.
  • Research Grants Program Grant-based funding for basic, translational, and clinical research to academic and industry researchers studying dysferlinopathy and CNNM2-associated diseases. The foundation solicits proposals and monitors funded project progress.
  • Study Recruitment Service Support for recruiting dysferlinopathy patients from the Dysferlin Registry for surveys, studies, and clinical trials, enabling researchers to access a trial-ready patient cohort.

Quantifiable outcome

  • 83% retention rate achieved in COS clinical study vs. 70% industry average
  • +3 more outcomes

Companies that use Jain Foundation

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Jain Foundation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Jain Foundation partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core and minor.

  • PROOF Centre of Excellence (Vancouver, BC, Canada)coreStrategic or Co-development PartnerCollaboration for biomarker discovery and validation in dysferlinopathy. PROOF Centre (Centre of Excellence for the Prevention of Organ Failure) provided expertise in computation, 'omic' science, and biomarker workflow. Project resulted in identification of blood-based biomarkers associated with differences in muscle function.
  • Wellstone Muscular Dystrophy Specialized Research Center (University of Iowa)coreStrategic or Co-development PartnerWellstone Center maintains a repository of broad spectrum of skeletal muscle biopsies from neuromuscular disease patients including dysferlinopathy. Provides biopsy samples to researchers upon request.
  • Jackson Laboratory (JAX)coreStrategic or Co-development PartnerJAX serves as the repository for multiple dysferlin-deficient mouse models (Bla/J cryopreserved stock, A/J, SJL/J, Dysf-/- lines, and others). The foundation maintains private live colonies that are distributed through JAX upon foundation approval. Also hosts the KI32 private colony.
  • WiCellminorStrategic or Co-development PartnerWiCell provides iPS cell lines from dysferlinopathy patients, including JFNY iPS line from a patient heterozygous for the c.5713C>T mutation. Part of the dysferlin-deficient collection.
  • GenethonminorStrategic or Co-development PartnerDr. Isabelle Richard at Genethon developed the Bla/J mouse strain by crossing the A/J dysferlin mutation onto C57BL/6 background. Strain was donated to Jackson Laboratory in collaboration with Jain Foundation.
  • Brigham and Women's Hospital, Harvard Medical SchoolcoreStrategic or Co-development PartnerResearch collaboration on macrophage-mediated mechanisms in dysferlinopathy pathogenesis. Dr. Vicki R Kelley leads studies on M1-like vs M2-like macrophage phenotypes and their role in non-resolving muscle inflammation.
  • Dr. Frances Lemckert (Children's Hospital at Westmead & Children's Medical Research Institute)coreStrategic or Co-development PartnerCollaboration on proteomics and lipidomics analysis of dysferlin-deficient muscle, including studies on exon 40a knockout mice. Generated comprehensive datasets from 18-week old mice quadricep muscles.
  • Dr. Bradley S. Launikonis (University of Queensland)coreStrategic or Co-development PartnerResearch on calcium handling and ryanodine receptor (RyR1) in dysferlinopathy. Study published in Nature Communications (2025) showing how dysferlin deficiency impacts calcium leak through RyR1 and how this relates to muscle-specific pathology.
  • Dr. Pascal Bernatchez (University of British Columbia)coreStrategic or Co-development PartnerResearch on the link between dysferlin and cholesterol metabolism. Studies show ApoE knockout mice crossed with dysferlin-deficient mice develop worse muscle phenotype, indicating cholesterol may play a role in muscular dystrophy.
  • Dr. Christoph Handschin (University of Basel)coreStrategic or Co-development PartnerResearch on metabolic dysregulation in dysferlinopathy. Study published in Life Sci Alliance (2025) revealing unexpected role for dysferlin in muscle cell energy metabolism and showing PGC-1alpha overexpression accelerates disease.
  • Dr. Doug Anderson (University of Rochester)coreStrategic or Co-development PartnerDevelopment of StitchR technology for full-length dysferlin protein expression using dual AAV vector approach. Technology 'stitches' together two RNA fragments to create full-length transcripts for large gene delivery.
  • Dr. Volker Straub (John Walton Muscular Dystrophy Research Center, Newcastle University)coreStrategic or Co-development PartnerLeadership of International Clinical Outcome Study (COS) for Dysferlinopathy. Team provided patient data for studies on respiratory impairment prediction using upper limb assessments.
  • Dr. Miranda Grounds (University of Western Australia)coreStrategic or Co-development PartnerResearch on mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy. Study investigates why daily glucocorticoid administration causes accelerated muscle strength loss in dysferlinopathy patients.
  • TREAT-NMDminorGTM or Marketing PartnerInternational conference partnership for neuromuscular disease research. Foundation provides travel grants for researchers presenting dysferlin-related work at TREAT-NMD conferences.
  • Muscular Dystrophy Association (MDA)minorGTM or Marketing PartnerAnnual conference partnership. Foundation staff attend MDA Clinical & Scientific Conference to engage with the muscular dystrophy research community and share dysferlin-specific research.
  • Nationwide Children's HospitalcoreStrategic or Co-development PartnerClinical site for gene therapy trial in dysferlinopathy using AAVrh74 vector. Trial focuses on non-ambulant patients age 18+ with established DYSF mutations on both alleles.
  • CNNM2 Patients and ResearcherscoreStrategic or Co-development PartnerNew program (September 2025) investigating diseases related to CNNM2 gene mutations affecting magnesium handling. Foundation provides dedicated emails (CNNM2ResearchFunding@jain-foundation.org, CNNM2Patients@jain-foundation.org) and is developing research tools including CNNM2 mouse models and cell lines.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Jain Foundation competitors and assessment

Company assessment

Direct peers

  • Coalition to Cure Calpain 3 (C3): Patient-founded nonprofit focused on finding treatments for LGMD2A/R1 (calpain 3 deficiency). Operates an almost identical playbook to Jain: maintains a patient registry, funds academic research, and provides free research tools to the field. The most direct structural analog to the Jain Foundation within the LGMD nonprofit ecosystem.
  • Parent Project Muscular Dystrophy (PPMD): Disease-specific nonprofit dedicated to Duchenne muscular dystrophy. Operates a patient registry, funds research, develops standards of care, and partners with industry on clinical trials. Same patient-founded, vertically integrated rare-disease foundation model that Jain has applied to dysferlinopathy.
  • Speak Foundation: Dysferlinopathy-focused patient foundation providing support, education, and advocacy for individuals with LGMD2B/R2 and Miyoshi Myopathy. Directly overlaps with Jain's patient community and serves as a complementary peer in the same disease space.
  • FSHD Society: Patient-driven nonprofit focused on facioscapulohumeral muscular dystrophy. Operates a patient registry, funds research, and convenes the field through scientific meetings — the same integrated model Jain uses for dysferlinopathy. Comparable rare-disease foundation structure.
  • Cure SMA: Spinal muscular atrophy nonprofit that has driven one of the most successful translational models in rare disease, including standards of care, patient registries, and partnered clinical trials. Functions as a benchmark for what a well-run disease-specific rare disease research foundation can achieve.
  • Myotonic Dystrophy Foundation (MDF): Patient-founded nonprofit focused on myotonic dystrophy (DM1/DM2). Maintains a patient registry, funds research grants, and convenes an annual scientific meeting. Comparable to Jain in scope, scale, and operating model within the muscular dystrophy nonprofit ecosystem.
  • AFM-Téléthon: French neuromuscular disease nonprofit and parent of Généthon, which developed the Bla/J dysferlin mouse strain now maintained by Jain. The closest European analog to a vertically integrated rare-disease research foundation, combining fundraising, gene therapy development, and clinical infrastructure.

Broad incumbents

  • Muscular Dystrophy Association (MDA): Large, established muscular dystrophy nonprofit supporting research and care across all MD subtypes including dysferlinopathy. Operates MDA Care Centers, a broad research grant program, and an annual Clinical & Scientific Conference. Broader and more diversified than Jain, but overlaps significantly on patient support and research funding.
  • TREAT-NMD Alliance: International network for neuromuscular disease research and clinical trial infrastructure, including patient registries and care standards. Partners with Jain on conference grants and convening; relevant as a cross-disease infrastructure peer rather than a direct fundraiser.

Others

  • National Organization for Rare Disorders (NORD): Umbrella advocacy organization for the rare-disease community in the US, providing policy advocacy, patient assistance programs, and convening for disease-specific organizations like Jain. Adjacent rather than competitive, but a key peer in the rare-disease ecosystem in which Jain operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Jain Foundation social profiles

Digital presence

Jain Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jain Foundation leadership team

Management profile

Number of profiles

Profiles9 records

Jain Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jain Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jain Foundation

What does Jain Foundation do?

The Jain Foundation is a non-profit research foundation that funds, coordinates, and conducts research to find cures for dysferlinopathy (LGMD2B/LGMDR2/Miyoshi Myopathy 1) and CNNM2-associated diseases. It provides free research tools (animal models, cell lines, antibodies, DNA constructs), human biospecimens, natural history clinical data, preclinical MRI platform services, and a patient registry to support basic, translational, and clinical research globally.

Is Jain Foundation a public or private company?

Jain Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Jain Foundation founded?

Jain Foundation was founded in 2005. It employs 1 to 10 people.

Where is Jain Foundation based?

Jain Foundation is headquartered in Seattle, United States, in the North America region.

How does Jain Foundation make money?

One revenue line is on record: endowment and Family Funding.

Who are Jain Foundation's main competitors?

Direct peers on record are Coalition to Cure Calpain 3 (C3), Parent Project Muscular Dystrophy (PPMD), Speak Foundation, FSHD Society, Cure SMA, Myotonic Dystrophy Foundation (MDF) and AFM-Téléthon. Broad incumbents are Muscular Dystrophy Association (MDA) and TREAT-NMD Alliance. National Organization for Rare Disorders (NORD) is listed as an others.

Does Jain Foundation have an API?

No public API is recorded for Jain Foundation.

What industry is Jain Foundation in?

Jain Foundation's product category is Muscular Dystrophy Research. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsKinea Bio Receives Up To $1.1M Commitment From Jain FoundationKinea Bio, a Seattle biotech, received up to $1.1M from Jain Foundation for IND-enabling activities, including dose-finding and GLP toxicology studies in dysferlin-deficient animal models. The company is developing a dual AAV vector platform and in-licensed a clinically validated AAV capsid for skeletal muscle delivery.Business Wire BlogKinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular DiseaseKinea Bio announced a $1.1M Jain Foundation investment and a license to Solid Biosciences' AAV-SLB101 capsid to advance its dual-AAV gene therapy KNA-155 for dysferlinopathy. The funding will support IND-enabling studies, and the capsid will enable muscle-targeted delivery. The company aims to move toward first-in-human trials.YahooKinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular DiseaseKinea Bio Inc. announced that the Jain Foundation has committed up to $1.1 million in milestone-based funding to support IND-enabling preclinical studies for KNA-155, the company's dual-AAV gene therapy candidate for dysferlinopathy, a rare neuromuscular disease. The funding will cover dose-finding and GLP toxicology studies in dysferlin-deficient animal models to define the therapeutic window and generate pivotal safety data. Kinea Bio also secured a non-exclusive license from Solid Biosciences for its next-generation myotropic AAV capsid, AAV-SLB101, to serve as the delivery vehicle for KNA-155 in systemic administration.Business Wire BlogKinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular DiseaseKinea Bio Inc. announced two major achievements advancing its gene therapy program for dysferlinopathy, a rare progressive muscular dystrophy with no approved treatments. The Jain Foundation committed up to $1.1 million in milestone-based funding to support IND-enabling preclinical studies, while Solid Biosciences granted a strategic license for its AAV-SLB101 myotropic capsid to enable muscle-targeted delivery. These developments provide scientific and financial foundation for KNA-155, Kinea Bio's dual-AAV gene therapy candidate.GlobeNewswireJain Foundation Signs Agreement With Cellular Dynamics to Create iPSC Lines From Patients With Muscular DystrophiesThe Jain Foundation signed a Master Service Agreement with Cellular Dynamics International to create five induced pluripotent stem cell lines from patients with dysferlin-related muscular dystrophies. The iPSC lines will model the diseases for drug discovery, as no effective treatments currently exist. Terms of the agreement were not disclosed.GlobeNewswireEvotec and the Jain Foundation Announce Extension of Research Collaboration in Skeletal Muscular Dystrophy DiseasesEvotec and the Jain Foundation extended their research collaboration to expand screening capabilities for dysferlinopathy. The partnership aims to develop a cell-based assay to identify compounds that improve muscle cell well-being in dysferlin-deficient cells. No financial details were disclosed.